Transplant glomerulopathy (TG) is a manifestation of chronic AMR with a poor prognosis and no specific treatment. Although the association between TG and anti HLA antibodies [Abs] is well known, there are few studies linking the nature of these Abs to outcome. 55 patients with TG (33M, 22F, mean age 47.5±12.1 yrs, mean time to TG diagnosis 9.32±8.37 yrs, mean follow up 26.6±18.0 months) were studied. Stored serum samples from the time of TG diagnosis were analysed for the presence of IgG and IgM HLA, DSA and Complement fixing antibodies. 52/55 (94.5%) patients were HLA Ab+, 3/55 were IgG HLA Ab- and 1 patient was IgM HLA Ab+. 27/55 (49.1%) had IgG HLA DSAs, 2/27 had class I alone, 15/27 had class II alone and 10/27 had both class I+II. Overall 39/55 (69.1%) patients had Abs directed against DQ (21/39 were DSAbs, 18/39 were HLA). 24/55 (43.6%) patients had C1q+ antibodies; 2/24 (8.3%) had a C1q+ class I DSA, 16/24 (66.7%) had a C1q+ class II DSA, 3/24 (12.5%) had a C1q+ class I non DSA HLA and 3/24 (12.5%) had a C1q+ class II non DSA HLA. 16/24 (66.7%) of patients had C1q+ antibodies against DQ. Overall allograft survival was 70.8%, 35.3%, 27.2% and 15.5% at 12, 36, 48 and 60 months respectively, mean 26.4±17.7 months. Allograft survival was significantly worse in IgG DSA+ patients compared with IgG DSA- patients.Figure: No Caption available.(see Figure 1, log rank test p=0.04). The IgG DSA MFI had no effect on allograft survival. There was no difference in allograft survival in C1q+patients (p=0.88) although the presence of C1q+ Ab was associated with the presence of C4d on allograft biopsy (p=0.01).This study shows that the presence of IgG DSAs is associated with inferior allograft survival in patients with TG. This group of patients may benefit from more aggressive therapy. DISCLOSURES:Lawrence, C.: Other, Honoraria from OneLambda, speakers fee from OneLambda.